Doucet D, Idée J M
Laboratoire Guerbet, Aulnay-Sous-Bois, France.
Ann Radiol (Paris). 1992;35(4 Pt 2):267-72.
The authors summarize the results of the main preclinical studies conducted to evaluate the tolerance of ioversol (Optiray), a new non ionic Low Osmolality Contrast Medium (LOCM). The various studies conducted by different routes of administration, in a number of animal species and at different dosages led to the conclusion that the product was equivalent or superior to the other non ionic agents used as references. This high inertia towards the biological systems particularly well evidenced in the neurologic tolerance studies has to be relied to the non ionic LOCM character of the agent but also to its highest hydrophilicity in its class and to the good distribution of this hydrophilicity around the molecule. These physiochemical characteristics which differentiate ioversol from the other products of its class make it a promising product for clinical use in humans.
作者总结了为评估新型非离子低渗造影剂(LOCM)碘海醇(欧乃派克)的耐受性而进行的主要临床前研究结果。通过不同给药途径,在多种动物物种中以及不同剂量下开展的各项研究得出结论,该产品与用作对照的其他非离子制剂相当或更优。在神经耐受性研究中特别明显体现出的对生物系统的这种高惰性,既归因于该制剂的非离子低渗造影剂特性,也归因于其在同类产品中最高的亲水性以及这种亲水性在分子周围的良好分布。碘海醇与其同类其他产品不同的这些物理化学特性,使其成为一种有望用于人类临床的产品。